BTIG Stands Firm on Abbott Buy Rating as ABT Trades Near 52-Week Lows
By TrendSpider Editor
BTIG analyst Marie Thibault reaffirmed a Buy rating on Abbott Laboratories with an unchanged price target of $131, a signal of conviction at a time when ABT is trading well below that level. Shares are currently priced at $93.93, up 1.16% on the session, but remain deep in the lower half of their 52
BTIG Stands Firm on Abbott Buy Rating as ABT Trades Near 52-Week Lows
BTIG analyst Marie Thibault reaffirmed a Buy rating on Abbott Laboratories with an unchanged price target of $131, a signal of conviction at a time when ABT is trading well below that level. Shares are currently priced at $93.93, up 1.16% on the session, but remain deep in the lower half of their 52-week range of $90.72 to $139.05. The confirmation comes with the stock hovering just above its 52-week floor, making the analyst's maintained bullish stance all the more notable.
Key Drivers of the ABT Stock Move
- Main Catalyst: BTIG's Marie Thibault confirmed a Buy rating on ABT with a price target of $131, unchanged from her prior target. The reaffirmation is a clear signal that the firm sees no reason to walk back optimism despite the stock's significant decline from its 52-week high.
- Bull Case: The $131 price target represents substantial upside from the current price of $93.93, implying meaningful appreciation potential from current levels. With shares sitting near the 52-week low of $90.72, a Buy confirmation from a sell-side analyst suggests the risk/reward setup may be tilting in favor of patient buyers.
- Bear Case: ABT has traded as high as $139.05 over the past year and is now more than 32% off that peak, suggesting persistent selling pressure that a single rating confirmation may not be enough to reverse. The proximity to the 52-week low of $90.72 also raises the question of whether the floor has truly been established.
Abbott enters this analyst reaffirmation in a complicated operating environment. The medical device and diagnostics giant has faced headwinds that have weighed on shares over the past several months, and today's modest bounce of 1.16% reflects cautious optimism rather than a definitive trend reversal. With ABT sitting just $3.21 above its 52-week low, the coming sessions will be important in determining whether the stock can build on today's gain or whether broader market pressure continues to drag it toward technical support levels. BTIG's unchanged price target of $131 provides a long-term anchor for bulls, but the path from $93.93 to that target will require either improved fundamentals or a shift in market sentiment toward the healthcare sector.
ABT Analyst Ratings and Price Targets
BTIG analyst Marie Thibault confirmed her Buy rating on Abbott Laboratories on April 28, 2026, with a price target of $131, matching her prior target of $131. No upgrade or downgrade was issued. The average price target across tracked analyst actions stands at $131.
ABT Seasonality
Late April has historically been an active period for Abbott given the company's quarterly earnings cycle, which often draws renewed analyst attention and price target reviews in this window. Analyst rating confirmations around this time of year tend to reflect updated views following earnings disclosures or management guidance updates.
ABT Relative Performance
ABT's 1.16% gain on Tuesday puts it in positive territory for the session, though the stock remains under significant pressure relative to its 52-week high of $139.05. Trading at $93.93, Abbott is lagging the performance implied by its analyst consensus and is outpacing its 52-week low of $90.72 by only a narrow margin, suggesting the stock continues to underperform its longer-term potential as reflected in BTIG's maintained $131 price target.